Open Orphan Plc (GB:HVO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Open Orphan Plc, a leading specialist contract research organisation, is set to release its interim results for the first half of 2024 on September 10. The company, known for its expertise in human challenge clinical trials for infectious and respiratory diseases, invites shareholders and potential investors to a live presentation on the same day. hVIVO, under the Open Orphan umbrella, operates the world’s largest commercial human challenge trial unit in London and has a significant repeat client base, including major global biopharma companies.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.